BCL-2 is known to be a good target for MCL (Davids, 2017; Khan and Kahl, 2018), and the clinical outcomes also showed that combined treatment using ibrutinib and BCL-2 antagonist venetoclax enhanced clinical responses (Pascual et al., 1998; Killock, 2018). The gene discussed is BCL2; the disease is mantle cell lymphoma.